澳大利亚药物经济学评价指南及其借鉴  

Australian Pharmacoeconomics Evaluation Guidelines and its Reference

作　　者：苏霞 李惠军 孙鹤[1,3,4,5] SU Xia;LI Hui-jun;SUN He(Tianjin University,Tianjin 300072,China;Earnest&Yea-saying Med-Tech(Beijing)Co.,Ltd.,Beijing 100024,China;Tasly Academy,Tasly Holding Group Co.,Ltd.,Tianjin 300410,China;Tasly Group State Key Laboratory of Core Technology in Innovative Chinese Medicine Development,Tianjin 300410,China;Axeon Biomedicine Globalization Co.,Ltd.,Tianjin 300410,China)

机构地区：[1]天津大学,天津300072 [2]恩远医药科技(北京)有限公司,北京100024 [3]天士力集团有限公司研究院,天津300410 [4]天士力集团创新中药关键技术国家重点实验室,天津300410 [5]天津雅昂医药国际化生产力促进中心,天津300410

出　　处：《中国合理用药探索》2021年第7期10-14,共5页Chinese Journal of Rational Drug Use

摘　　要：为推进药物经济学评价应用于我国药品注册和药品报销,本文在研究澳大利亚药品注册现状及药品注册中关于药物经济学评价的规定基础上,合理借鉴其宝贵经验并建议:重视药物经济学在药品决策中的作用,并根据实际情况修订指导性指南,更新医保目录,逐步探索适合我国药物经济学评价的标准,更好地发挥其在决策过程中的应用。Australia has a relatively complete drug registration process and pharmacoeconomics evaluation guidelines.In order to promote the application of pharmacoeconomic evaluation in drug registration and reimbursement in China,this paper introduces the current situation of drug registration in Australia and the regulations on pharmacoeconomic evaluation in drug registration,so as to draw on its valuable experience and provide suggests:We should pay attention to the role of pharmacoeconomics in drug decision-making,revise the guiding guidelines according to the actual situation,update the medical insurance catalog,and gradually explore the criteria suitable for pharmacoeconomics evaluation in China and improve its application in the decision-making process.

关 键 词：药物经济学 规范 药品注册 药品报销 建议 

分 类 号：R956[医药卫生—药学]